Macroalbuminuria and microalbuminuria: Do both predict renal and cardiovascular events with similar strength?

Journal of Nephrology

Volumn 20, Issue 4, 2007, Pages 375-380

  de Jong, Paul E ^a   Gansevoort, Ron T ^a   Bakker, Stephan J L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cardiovascular risk; Macroalbuminuria; Microalbuminuria; Proteinuria; Renal risk

Indexed keywords

ALBUMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOSARTAN; PLACEBO;

ALBUMINURIA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; ESSENTIAL HYPERTENSION; HUMAN; KIDNEY DISEASE; MICROALBUMINURIA; PREDICTION; PROGNOSIS; PROTEIN DEPLETION; SCREENING;

ALBUMINURIA; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY DISEASES; PROGNOSIS; RISK;

EID: 36048929086     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Nelson RG, Bennet PH, Beck GJ, Tan M, Knowler WC, Mitch WE, Hirschman GH, Myers BD. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. N Engl J Med 1996; 335: 1636-42.
2. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snappin S, Cooper ME, Mitch WE, Brenner BM. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-20.
3. Agodoa LY, Appel L, Bakris GL Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowle D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT, Xu S; African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285: 2719-28.
4. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS; AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139: 244-52.
5. Ruggenenti P, Perna A, Remuzzi G. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003; 63: 2254-61.
6. Eijkelkamp WBA, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gelim GW, Weir MR, Brenner BM, de Zeeuw D. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the RENAAL trial. J Am Soc Nephrol 2007; 18: 1540-6.
7. de Jong PE, Navis GJ, de Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet 1999; 354: 352-3.
8. Hillege HL, Janssen WMT, Bak AAA, Diercks GF, Grobbee DE, Crijns HJ, Van Gilst WH, De Zeeuw D, De Jong PE; Prevend Study Group. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249: 519-26.
9. Halbesma N, Kuiken DS, Brantsma AH, Bakker SJL, Wetzels JFM, de Zeeuw D, de Jong PE, Gansevoort RT; for the PREVEND study group. Macroalbuminuria is a better risk marker than low GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol 2006; 17: 2582-90.
10. Rossing P, Hougaard P, Borch-Johnsen K, Parving HH. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ 1996; 313: 779-84.
11. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Brenner BM. Albuminuria therapeutic target for cardiovascular protection in type 2 diabetic nephropathy. Circulation 2004; 110: 921-7.
12. Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with the nephrotic syndrome. Kidney Int 1993; 44: 638-42.
13. Gerstein HC, Mann JF, Yi Q, Zinman D, Dinneen SF, Hoogwerf B, Halle JP, Rashkow A, Joyce C, Nawaz S, Yusuf S. Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-6.
14. Parving H-H, Oxenboll B, Svendsen PA, Christiansen JS, Andersen AR. Early detection of patients at risk of developing diabetic nephropathy. Acta Endocrinol 1982; 100: 550-5.
15. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984; 311: 89-93.
16. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16: 1325-33.
17. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003; 63: 1468-74.
18. Ishani A, Grandits GA, Grimm RH, Svendsen KH, Collins AJ, Prineas RJ, Neaton JD; for the MRFIT research group. Association of single measurements of dipstick proteinuria, eGFR, and hematocrit with 25yr incidence of end stage renal disease in the MRFIT. J Am Soc Nephrol 2006; 17: 1444-52.
19. Konta T, Hao Z, Takasaki S, Abiko H, Takahashi T, Ichikawa K, Ikeda A, Ishikawa M, Kawata S, Kato T, Kubota I. Clinical utility of trace proteinuria for microalbuminuria screening in the general population. Clin Exp Nephrol 2007; 11: 51-5.
20. Verhave JC, Gansevoort RT, Hillege HL, Bakker SJ, De Zeeuw D, de Jong PE; PREVEND Study Group. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int Suppl 2004; (92): S18-21.
21. Halbesma N, Brantsma AH, Bakker SJL, Stolk RP, de Zeeuw D, de Jong PE, Gansevoort RT; for the PREVEND study group. Predictors of renal function decline during 6 years follow-up in the general population. J Am Soc Nephrol 2006; 17: 203A.
22. Halimi JM, Buchler M, Al-Najjar A, Laouad I, Chatelet V, Marliere JF, Nivet H, Lebranchu Y. Urinary albumin excretion and the risk of graft loss and death in proteinuric and non-proteinuric renal transplant recipients. Am J Transplant 2007; 7: 618-25.
23. Wachtell E, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup R Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139: 901-6.
24. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990; 300: 297-300.
25. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion: an independent predictor of ischemic heart disease. Arterioscier Thromb Vasc Biol 1999; 19: 1992-7.
26. Hillege HL, Fidler V, Diercks GFH, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and non-cardiovascular mortality in general population. Circulation 2002; 606: 1777-82.
27. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, Appleyard M, Jensen JS. Very low levels of microalbuminuria are associated with increased risk of coronary heart death and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110: 32-5.
28. Messent JWC, Elliott TG, Hill RD, Jarrett RJ, Keen H, Viberti GC. Prognostic significance of microalbuminuria in insulin dependent diabetes mellitus: a twenty-three year follow-up study. Kidney Int 1992; 41: 836-9.
29. Palmer AJ, Annemans L, Roze S, Lamotte M, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH. Cost-effectiveness of early irbesartan treatment versus control or late irbesartan treatment in patients with type 2 diabetes, hypertension and renal disease. Diabetes Care 2004; 27: 1897-903.
30. Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA 2003; 290: 3101-14.
31. Gansevoort RT, de Jong PE, Postma MJ. Cost effectiveness of screening for proteinuria. JAMA 2004; 291: 1442-3.
32. Atthobari J, Asselbergs FW, Boersma C, de Vries R, Hillege HL, van Gilst WH, Gansevoort RT, de Jong PE, de Jong-van den Berg LTW. Cost-effectiveness of screening for albuminuria and subsequent treatment with an ACE inhibitor to prevent cardiovascular events: a pharmacoeconomic analysis linked to the PREVEND and the PREVEND IT studies. Clin Ther 2006; 28: 432-44.